Tag: infants

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) --

About Shriners Hospitals for Children Canada
Established in Montreal in 1925, Shriners Hospitals for Children Canada is a bilingual, short-term, acute care hospital, providing ultra-specialized orthopaedic care to children from across Canada and around the world. The mission of the hospital is to provide treatment and rehabilitation to infants, children and young adults with orthopaedic and neuromuscular problems such as scoliosis, osteogenesis imperfecta (brittle bone disease), clubfeet, hip dysplasia, leg length discrepancies and cerebral palsy, among others. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital provides clinical experience and teaching for residents and allied professionals within its outstanding new facility on the Glen site. The hospital is present in communities across Canada, thanks to telemedicine, outreach clinics and satellite clinics.

NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 and July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline.

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Reckitt (RBGLY) To Contact Him Directly To Discuss Their Options

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

NEW YORK and NEW ORLEANS, July 22, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 4, 2025 to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY), if they purchased the Company’s American Depositary Shares (“ADSs”) between January 13, 2021 and July 28, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 and July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline.